• Publications
  • Influence
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Millefosine, paromomycin and liposomal amphotericin B are gradually replacing pentavalent antimonials and conventional amphoteric in B as the preferred treatments in some regions, but in other areas these drugs are still being evaluated in both mono- and combination therapies. Expand
Drug Resistance in Leishmaniasis
It is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy. Expand
Drug Resistance in Leishmaniasis
It is important that effective monitoring of drug use and response should be done to prevent the spread of resistance andimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance. Expand
Laboratory Diagnosis of Visceral Leishmaniasis
  • S. Sundar, M. Rai
  • Biology, Medicine
  • Clinical and Vaccine Immunology
  • 1 September 2002
The group of diseases known as the leishmaniases are caused by obligate intracellular protozoa of the genus Leishmania ([39][1]). Natural transmission of leishmania is carried out by a certainExpand
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
In India, 320 patients with visceral leishmaniasis received identical pentavalent antimony (Sb) treatment, and Sb induced long-term cure in 35% of those in Bihar versus 86% (95% CI, 79%-93%) of Those in Uttar Pradesh. Expand
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis
The results did not point to an important role for natural CD4+CD25+ (Foxp3high) T reg cells in human VL, but elevated levels of IL-10 in VL plasma significantly enhanced the growth of L. donovani amastigotes in human macrophages. Expand
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.
The current situation and perspectives for diagnosis, treatment, and control of visceral leishmaniasis are reviewed, and some priorities for research and development are listed. Expand
Drug resistance in Indian visceral leishmaniasis
  • S. Sundar
  • Medicine
  • Tropical medicine & international health : TM…
  • 1 November 2001
Despite several disadvantages, amphotericin B is the only drug available for use in these areas and should be used as first‐line drug instead of Sbv, and the new oral antileishmanial drug miltefosine is likely to be the first-line drug in future. Expand
Oral miltefosine for Indian visceral leishmaniasis.
Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis and may also be helpful in regions where parasites are resistant to current agents. Expand
Drug Uptake and Modulation of Drug Resistance in Leishmania by an Aquaglyceroporin*
This is the first report of the uptake of a metalloid drug by an aquaglyceroporin in Leishmania, suggesting a strategy to reverse resistance in the field. Expand